Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study

BACKGROUND: Basal cell carcinomas (BCCs) exhibit aberrant activation of the hedgehog pathway. Sonidegib is a hedgehog pathway inhibitor approved for the treatment of locally advanced BCC (laBCC) and metastatic BCC (mBCC) based on primary results of the BOLT study [Basal Cell Carcinoma Outcomes with...

Descripción completa

Detalles Bibliográficos
Autores principales: Dummer, R., Guminksi, A., Gutzmer, R., Lear, J.T., Lewis, K.D., Chang, A.L.S., Combemale, P., Dirix, L., Kaatz, M., Kudchadkar, R., Loquai, C., Plummer, R., Schulze, H.‐J., Stratigos, A.J., Trefzer, U., Squittieri, N., Migden, M.R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318253/
https://www.ncbi.nlm.nih.gov/pubmed/31545507
http://dx.doi.org/10.1111/bjd.18552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318253/
https://www.ncbi.nlm.nih.gov/pubmed/31545507
http://dx.doi.org/10.1111/bjd.18552

Ejemplares similares